Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / Des-ubiquitin



This biomarker is also known as:
  • des-Gly-Gly-ubiquitin,

View in BioMuta


Des-ubiquitin is formed when a cysteine protease cleaves two carboxy-terminal glycine residues from ubiquitin.


QA State: Curated
Type: Proteomic
Short Name:
HGNC Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: One
QA State: Under Review


Cathepsin B, which is a cysteine protease, cleaves 2 terminal glycine residues of ubiquitin generating des-ubiquitin. Both monomeric ubiquitin and des-ubiquitin corresponding to m/z values 8,565 and 8,451 are among the 9 candidates of the signature described in the Rahman 9-marker MALDI MS panel for Lung Cancer study.

Performance Comment

Des-ubiquitin belongs to a 9-member panel that provides a quantitative measure of the probability of having lung cancer that goes beyond the histological evaluation of preinvasive lesions. The identified members of the panel are TMSB4X (Thymosin beta-4), Ubiquitin, des-ubiquitin, ACBP, CSTA, Cytochrome C, and MIF.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated resources found.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 02/12/2015

Please register for the 29th EDRN Steering Committee Meeting in Atlanta, GA from March 31-April 2, 2015. The registration page has information about booking hotel rooms and a draft agenda of the meeting.